Showing results (91-100 of 177) with videos related to
Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Prognostic factors for children with Hodgkin's disease treated with combined-modality therapyRon S Smith, Qing Chen, Melissa M Hudson, et al.International Journal of Radiation Oncology, Biology, Physics|October 1, 2013
The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803Aaron C Spalding, Douglas S Hawkins, Sarah S Donaldson, et al.International Journal of Radiation Oncology, Biology, Physics|November 23, 2011
Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 studyJohn Breneman, Jane Meza, Sarah S Donaldson, et al.Pediatric Blood & Cancer|May 6, 2004
Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997R Beverly Raney, Julie A Stoner, David O Walterhouse, et al.American Journal of Clinical Oncology|January 7, 2014
Breast Imaging in Women Previously Irradiated for Hodgkin LymphomaKathleen C Horst, Katherine E Fero, Steven L Hancock, et al.Journal of the National Cancer Institute|July 17, 2010
Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor StudyDebra L Friedman, John Whitton, Wendy Leisenring, et al.Journal of Pediatric Hematology/Oncology|March 11, 2014
Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology GroupRichard L Tower, Tamekia L Jones, Bruce M Camitta, et al.Pediatric Blood & Cancer|February 7, 2022
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trialsJosephine H Haduong, Christine M Heske, Wendy Allen-Rhoades, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2004
Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology groupSheri L Spunt, Lynette M Smith, Frederick B Ruymann, et al.International Journal of Radiation Oncology, Biology, Physics|August 24, 2018
Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology GroupJulie A Bradley, Mark L Kayton, Yueh-Yun Chi, et al.Pageof 18